IRVINE, Calif., Feb. 11, 2008 (PRIME NEWSWIRE) -- "As a result of ever-increasing healthcare costs, managed care payers have stepped up their efforts to control certain expenses related to 'biologics' - a wide range of medicinal products that includes vaccines, blood and blood components, allergenics, cells and gene therapies, tissues, and proteins created in the laboratories of biotechnology companies using cutting-edge science," stated SmallCap Sentinel analyst D.R. Clark. "The ability to demonstrate 'value' based upon positive outcomes of patients using a particular biologic becomes a critical issue in making a decision about covering costs of such biologics. In this month's issue of the medical journal Nature Biotechnology, CardioVascular BioTherapeutics, Inc's (OTCBB:CVBT) is featured as an example of a smaller, more nimble biotech company that is ideally positioned to quickly adapt its development and commercialization processes to the current environment, centralizing healthcare value and capitalizing on the opportunities under the new review system."
The article can be reviewed at the following link http://stockupticks.com/profiles/2-8-08.html and also contains data and information of interest to cardiac-related companies including CVBT, Boston Scientific Corporation (NYSE:BSX), Medtronic, Inc., (NYSE:MDT), and Cardium Therapeutics, Inc. (AMEX:CXM).
"CVBT's inclusion in this widely-read journal points to its growing importance within the biotherapeutics space," Clark added.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase Ib or Phase II trial to treat dermal wound healing in diabetics (CVBT-141B) is planned to begin in 2008.
A related article, "The Battle for the Baby Boomers" has also been published at www.SmallCapSentinel.com
For ongoing information regarding the aforementioned public companies please register at:
http://stockupticks.com/register.html
To be featured in SmallCap Sentinel contact us at the number below.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been granted 20,000 restricted shares by CVBT for preparation and distribution of this report and other advertising. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.